Sanofi SA (SNY) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Acoziborole Winthrop for the treatment of both early and advanced-stage gambiense sleeping sickness in patients aged 12 years and older.
The recommendation was based on a Phase 2/3 study showing success rates of up to 96% at 18 months across both early and advanced stages of Trypanosoma brucei gambiense infection.
Human African trypanosomiasis, also known as sleeping sickness, is transmitted by the bite of an infected tsetse fly and is almost always fatal if left untreated.
Sanofi said it will donate Acoziborole Winthrop, co-developed with the Drugs for Neglected Diseases initiative (DNDi), to the World Health Organization through its philanthropic arm, Foundation S - The Sanofi Collective.
Sanofi shares closed at $48.35 on Thursday, up 1.60%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.